Genprex Reports Going Concern, Material Weaknesses, Raises $15.26M via ATM Amidst Nasdaq Delisting Threat

summarizeSummary

Genprex reported a going concern warning and material weaknesses in internal controls, while raising $15.26 million through dilutive ATM sales to extend its cash runway into H2 2027, all against the backdrop of a proposed second reverse stock split to maintain Nasdaq listing.

check_boxKey Events · Financing and Capital Events · GNPX

• Going Concern Warning Issued

  Management explicitly stated substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing, despite a cash runway extending into the second half of 2027.

• Significant Dilutive Capital Raise

  The company raised $13.36 million in Q1 2026 and an additional $1.90 million from April 1, 2026, through the filing date (May 13, 2026), via its At-The-Market (ATM) facility. This resulted in a substantial increase in outstanding shares from 3.29 million (Dec 31, 2025) to 9.04 million (Mar 31, 2026), with total outstanding shares reaching 10.59 million by May 11, 2026.

• Material Weaknesses in Internal Controls

  Disclosure controls and procedures were deemed ineffective as of March 31, 2026, due to a lack of segregation of duties and insufficient in-house accounting personnel for complex transactions. Remediation efforts are underway.

• Upcoming Reverse Stock Split Context

  This filing follows recent proxy statements (April 2026) seeking shareholder approval for another reverse stock split (1:5 to 1:50) to maintain Nasdaq listing, highlighting ongoing compliance challenges after a 1-for-50 reverse split in October 2025.

auto_awesomeAnalysis · GNPX · Life Sciences

Genprex's latest quarterly report reveals a critical financial situation, with management expressing substantial doubt about the company's ability to continue as a going concern. While the company successfully raised $15.26 million through its At-The-Market (ATM) facility in Q1 2026 and post-quarter, providing a cash runway into the second half of 2027, this capital came at the cost of significant shareholder dilution. Compounding these financial concerns are disclosed material weaknesses in internal controls over financial reporting. This filing also comes amidst recent proxy statements seeking approval for another reverse stock split, underscoring persistent Nasdaq listing compliance issues following a 1-for-50 reverse split in October 2025. Despite ongoing clinical progress in oncology and diabetes programs, the severe financial and governance challenges present a high risk for investors.